Terremoto Biosciences is a clinical-stage biotech company focused on designing highly selective, potent small-molecule AKT1 inhibitors. Its lead oncology program, TER-2013, is in Phase 1 clinical development for solid tumors harboring PIK3CA, AKT, or PTEN alterations. The company is also advancing TER-4480 for hereditary hemorrhagic telangiectasia, with clinical entry expected later this year. Terremoto emphasizes AKT1 selectivity to maximize efficacy while minimizing toxicities associated with AKT2 or PI3Kα inhibition. It is privately held and supported by investors including OrbiMed, Third Rock Ventures, Novo Holdings, Cormorant Asset Management, RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines. Terremoto is based in South San Francisco and San Diego.

Total raised

$358M

Funding rounds

3

Latest round

Series C

Latest activity

Apr 2026